These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 10430331)

  • 1. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial.
    Arora S; Katkov W; Cooley J; Kemp JA; Johnston DE; Schapiro RH; Podolsky D
    Hepatogastroenterology; 1999; 46(27):1724-9. PubMed ID: 10430331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.
    Feagan BG; Fedorak RN; Irvine EJ; Wild G; Sutherland L; Steinhart AH; Greenberg GR; Koval J; Wong CJ; Hopkins M; Hanauer SB; McDonald JW
    N Engl J Med; 2000 Jun; 342(22):1627-32. PubMed ID: 10833208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators.
    Feagan BG; Rochon J; Fedorak RN; Irvine EJ; Wild G; Sutherland L; Steinhart AH; Greenberg GR; Gillies R; Hopkins M
    N Engl J Med; 1995 Feb; 332(5):292-7. PubMed ID: 7816064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited?
    Charpignon C; Beau P
    Gastroenterol Clin Biol; 2008 Feb; 32(2):153-7. PubMed ID: 18343615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
    Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ;
    Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease.
    Mansfield JC; Parkes M; Hawthorne AB; Forbes A; Probert CS; Perowne RC; Cooper A; Zeldis JB; Manning DC; Hawkey CJ
    Aliment Pharmacol Ther; 2007 Aug; 26(3):421-30. PubMed ID: 17635377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease.
    Turner D; Grossman AB; Rosh J; Kugathasan S; Gilman AR; Baldassano R; Griffiths AM
    Am J Gastroenterol; 2007 Dec; 102(12):2804-12; quiz 2803, 2813. PubMed ID: 18042110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methotrexate in Crohn's disease: long-term efficacy and toxicity.
    Lémann M; Zenjari T; Bouhnik Y; Cosnes J; Mesnard B; Rambaud JC; Modigliani R; Cortot A; Colombel JF
    Am J Gastroenterol; 2000 Jul; 95(7):1730-4. PubMed ID: 10925976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study.
    Omer B; Krebs S; Omer H; Noor TO
    Phytomedicine; 2007 Feb; 14(2-3):87-95. PubMed ID: 17240130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial.
    Lémann M; Mary JY; Duclos B; Veyrac M; Dupas JL; Delchier JC; Laharie D; Moreau J; Cadiot G; Picon L; Bourreille A; Sobahni I; Colombel JF;
    Gastroenterology; 2006 Apr; 130(4):1054-61. PubMed ID: 16618399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease.
    Selby W; Pavli P; Crotty B; Florin T; Radford-Smith G; Gibson P; Mitchell B; Connell W; Read R; Merrett M; Ee H; Hetzel D;
    Gastroenterology; 2007 Jun; 132(7):2313-9. PubMed ID: 17570206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study.
    Valentine JF; Fedorak RN; Feagan B; Fredlund P; Schmitt R; Ni P; Humphries TJ
    Gut; 2009 Oct; 58(10):1354-62. PubMed ID: 19505878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
    Tremaine WJ; Hanauer SB; Katz S; Winston BD; Levine JG; Persson T; Persson A;
    Am J Gastroenterol; 2002 Jul; 97(7):1748-54. PubMed ID: 12135030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
    Furst DE; Saag K; Fleischmann MR; Sherrer Y; Block JA; Schnitzer T; Rutstein J; Baldassare A; Kaine J; Calabrese L; Dietz F; Sack M; Senter RG; Wiesenhutter C; Schiff M; Stein CM; Satoi Y; Matsumoto A; Caldwell J; Harris RE; Moreland LW; Hurd E; Yocum D; Stamler DA
    Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind clinical trial for treatment of Crohn's disease by oral administration of Alequel, a mixture of autologous colon-extracted proteins: a patient-tailored approach.
    Margalit M; Israeli E; Shibolet O; Zigmond E; Klein A; Hemed N; Donegan JJ; Rabbani E; Goldin E; Ilan Y
    Am J Gastroenterol; 2006 Mar; 101(3):561-8. PubMed ID: 16542292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice.
    Domènech E; Mañosa M; Navarro M; Masnou H; Garcia-Planella E; Zabana Y; Cabré E; Gassull MA
    J Clin Gastroenterol; 2008 Apr; 42(4):395-9. PubMed ID: 18277899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
    Pope JE; Bellamy N; Seibold JR; Baron M; Ellman M; Carette S; Smith CD; Chalmers IM; Hong P; O'Hanlon D; Kaminska E; Markland J; Sibley J; Catoggio L; Furst DE
    Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.
    Reinisch W; Hommes DW; Van Assche G; Colombel JF; Gendre JP; Oldenburg B; Teml A; Geboes K; Ding H; Zhang L; Tang M; Cheng M; van Deventer SJ; Rutgeerts P; Pearce T
    Gut; 2006 Aug; 55(8):1138-44. PubMed ID: 16492717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators.
    Feagan BG; McDonald JW; Rochon J; Laupacis A; Fedorak RN; Kinnear D; Saibil F; Groll A; Archambault A; Gillies R
    N Engl J Med; 1994 Jun; 330(26):1846-51. PubMed ID: 8196727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.